EPO and neoplasm: However, a decrease of tumor size and downregulation of the HIF-2α specific genes PAI-1, CCND1, EPO, and GLUT-1 have been reported in ccRCC xenografts treated with PT-2385 (aka MK-3795), a new HIF-2α inhibitor [160].